Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040510 | PMC |
| http://dx.doi.org/10.1016/j.xinn.2022.100251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanding the utilization of binding pockets proves to be effective for noncovalent small molecule inhibitors against SARS-CoV-2 M.
Eur J Med Chem
March 2025
State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, 511436, China; Guangzhou National Laboratory, Guangzhou, 510005, China; Innovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, 510005, China; The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511436, China; University of South China, Hengyang, 421001, China. Electronic address:
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and continues to pose serious threats to global public health. The main protease (M) of SARS-CoV-2 is crucial for viral replication and its conservation, making it an attractive drug target. Here, we employed a structure-based drug design strategy to develop and optimize novel inhibitors targeting SARS-CoV-2 M.
View Article and Find Full Text PDFDuration of mild acute SARS-CoV-2 infections with Omicron depending on previous vaccinations and infections - Using data of the German DigiHero cohort study from post-pandemic winters 2022/2023 and 2023/2024.
J Infect Public Health
March 2025
Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, Halle 06112, Germany. Electronic address:
Objectives: Protection against severe course of SARS-CoV-2 infection after COVID-19 vaccination or infection was extensively studied. It is unknown whether this effect also translates into shortened duration of mild infections. We assessed the duration of symptoms depending on vaccination status and previous SARS-CoV-2 infections among individuals with a mild course of infection.
View Article and Find Full Text PDFComparative analysis of croup severity and treatment in pediatric patient: a study of COVID-19 positive vs. negative cases during peak Omicron.
BMC Pediatr
March 2025
Emergency devision, school of medicine, Bahrami hospital, Tehran University of Medical Science, Tehran, Iran.
Background: The Omicron variant of SARS-CoV-2 has been associated with unique clinical presentations in children, including croup-like symptoms such as barking cough, hoarseness, and respiratory distress. This study aimed to compare the clinical, laboratory, and treatment characteristics of hospitalized pediatric patients with croup who tested positive or negative for COVID-19 during the Omicron wave.
Methods: A retrospective, descriptive-analytical study was conducted on 111 pediatric patients hospitalized with croup at Bahrami Children's Hospital and the Children's Medical Center in Iran from January 21 to March 20, 2022.
Pharmacologic Treatment and Management of Coronavirus Disease 2019.
Infect Dis Clin North Am
March 2025
Division of Infectious Diseases, Houston Methodist Hospital, 6560 Fannin Street Scurlock tower, Suite 1512, Houston, TX 77030, USA.
Widespread vaccination, hybrid immunity, and reduced pathogenicity with circulating Omicron variants have decreased the rate of severe coronavirus disease 2019 (COVID-19) outcomes in the general population. Certain patients with COVID-19 remain at high risk for severe outcomes. Clinicians must individualize treatments based on expected benefits and relative harms for patients with mild-to-moderate COVID-19.
View Article and Find Full Text PDFTargeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
Vaccine
March 2025
Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; CimCure BV, Amsterdam, the Netherlands. Electronic address:
The spike glycoprotein is a key factor in the infection cycle of SARS-CoV-2, as it mediates both receptor recognition and membrane fusion by the virus. Therefore, in this study, we aimed to design a multi-peptide conjugate vaccine against SARS-CoV-2, targeting the early stages of the virus's life cycle. We used iBoost technology, which is designed to induce immune responses against low- or non-immunogenic epitopes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!